DIPG Long-Term Survival Research | Burzynski, Houston

Diffuse intrinsic pontine glioma, often called DIPG, is one of the most difficult pediatric brain tumors physicians face. The tumor forms in the brainstem, specifically in an area called the pons, which controls critical functions such as breathing, movement, and heart rate.

Because of where the tumor grows, surgery is usually not possible. The tumor cells are intertwined with vital nerve pathways, making removal extremely risky. DIPG most often affects children between the ages of five and ten and represents the majority of brainstem tumors seen in children.

Historically, this diagnosis has carried a very serious prognosis. Many families are told that treatment options are limited and that survival beyond a few years is uncommon. For this reason, research exploring new treatment approaches continues to be extremely important.

What Symptoms Can Occur With DIPG?

Symptoms of DIPG can develop quickly because the tumor forms in the brainstem, an area that controls many of the body’s essential functions. The brainstem helps regulate movement, coordination, eye control, and facial muscles, so even small changes in this area can affect how the body functions.

Early symptoms may sometimes appear subtle at first and gradually become more noticeable. In many cases, families begin to notice changes in balance, facial movement, or coordination before seeking medical evaluation.

• Trouble with balance or walking
• Weakness on one side of the body
• Changes in facial movement
• Difficulty with eye movement or double vision
• Headaches, nausea, or vomiting

What Did the 2025 Research Study Find?

A 2025 clinical study reviewed outcomes in patients with DIPG who were treated in Phase II trials involving Antineoplastons A10 and AS2-1 at Burzynski Clinic in Houston, Texas.

The analysis included 165 patients diagnosed with DIPG. Among them, a group of 28 patients experienced unusually long survival compared with what has historically been expected with this disease.

In this group:

• Some patients survived longer than 3 years
• Several survived more than 10 years
• Eight individuals lived more than 12 years
• The longest survival extended beyond 29 years

These findings attracted attention because DIPG has traditionally been associated with a much shorter survival timeframe. Long-term outcomes such as these are rare in the history of this disease.

Researchers also reported that some individuals who survived more than 12 years met the criteria often used to define cure.

Why Do Long-Term Survival Studies Matter?

Studies examining long-term survival can help physicians better understand how certain treatment strategies may influence cancer behavior over time. Even a small number of long-term survivors can provide important insights for future research.

Cancer research continues to move toward more personalized approaches. Instead of treating all tumors the same way, scientists increasingly study the genetic and molecular features that drive how a tumor grows.

Understanding these biological signals may help physicians develop strategies designed to target cancer cells more precisely.

Research and Personalized Care at Burzynski Clinic

At Burzynski Clinic in Houston, Texas, Dr. Stanislaw Burzynski has spent decades studying targeted treatment approaches for complex cancers, including difficult brain tumors such as DIPG.

His research has focused on therapies designed to influence the biological signals that allow cancer cells to grow and spread. This approach is often referred to as precision or personalized oncology.

“When I meet with families, I want them to know we look closely at the biology of each tumor,” says Dr. Stanislaw Burzynski. “Every case is unique, and our goal is to understand what is driving the disease so we can explore the most appropriate treatment strategy for that individual.”

Research into rare and aggressive cancers continues to evolve. Each study adds to the growing scientific understanding of how these diseases behave and how they may be treated in the future.

Educational purposes only. Not medical advice.